Related Experiment Video

Updated: May 6, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

Preetesh Jain1, Carlos Guillermo Romo, Hanna J Khoury

  • 1jcortes@mdanderson.org.

Haematologica
|November 5, 2013
PubMed
Abstract

No abstract available in PubMed .

Keywords:
chronic myeloid leukemiachronic phasee1a2ponatinib

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

960
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K

Related Experiment Videos

Last Updated: May 6, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

960
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

694
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
694

Articles linked to this work by shared authors, journal, and citation graph.

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Blood·2016

Assessing need for palliative care services for children in Mexico.

Journal of palliative medicine·2014

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

Blood·2013

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.

Clinical lymphoma, myeloma & leukemia·2012

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

Cancer·2012

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

Clinical lymphoma, myeloma & leukemia·2012

Prognostic significance of monotypic plasma cell infiltration of the bone marrow in patients with Waldenström macroglobulinemia.

Haematologica·2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

Haematologica·2026

Protecting sickle cell care during Ebola outbreaks.

Haematologica·2026

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Haematologica·2026

T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?

Haematologica·2026

Epidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era.

Haematologica·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us